Ogsiveo – Talk Bio

Immunome’s desmoid tumor drug varegacestat posts landmark Phase 3 results, setting up a potential challenge to Merck KGaA’s Ogsiveo

1 month ago talkbio0Tagged Fibromatosis, Aggressive, Frequency of Responses, gamma secretase inhibitor, Immunome, Infrequent, Merck KGaA, NDA, Neoplasms, Ogsiveo, Phase 3 RINGSIDE trial, Progression-Free Survival, varegacestat

Immunome; varegacestat; desmoid tumors; Phase 3 RINGSIDE trial; gamma secretase inhibitor; Merck KGaA; Ogsiveo; progression-free survival; objective response rate; rare tumors; oncology; NDA filing

Merck KGaA springs back into M&A game with $3.9B buyout of Pfizer spinout SpringWorks

9 months ago talkbio0Tagged disease treatments, Fibromatosis, Aggressive, Gomekli, KGaA, Merck KGaA, Neurofibromatosis 1, Ogsiveo, Pfizer, Pfizer/, pharmaceutical acquisition, SpringWorks

Pharmaceutical acquisition, rare disease treatments, Merck KGaA, SpringWorks Therapeutics, Ogsiveo, Gomekli, desmoid tumors, neurofibromatosis type 1 (NF1), Pfizer spinout